onr:"swepub:oai:prod.swepub.kib.ki.se:152940464"
Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:152940464" > Consensus proposal ...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 03907naa a2200673 4500 | |
| 001 | oai:prod.swepub.kib.ki.se:152940464 | |
| 003 | SwePub | |
| 008 | 240701s2023 | |||||||||||000 ||eng| | |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1529404642 URI |
| 024 | 7 | a https://doi.org/10.1182/blood.20220186042 DOI |
| 040 | a (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Zeidan, AM4 aut |
| 245 | 1 0 | a Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes |
| 264 | c 2023-02-01 | |
| 264 | 1 | b American Society of Hematology,c 2023 |
| 520 | a Myelodysplastic syndromes/neoplasms (MDS) are associated with variable clinical presentations and outcomes. The initial response criteria developed by the International Working Group (IWG) in 2000 have been used in clinical practice, clinical trials, regulatory reviews, and drug labels. While the IWG criteria were revised in 2006 and 2018 (the latter focusing on lower-risk disease), limitations persist in their application to higher-risk MDS and in their ability to fully capture clinical benefits of novel investigational drugs or to serve as valid surrogates for longer-term clinical endpoints (e.g., overall survival). Further, issues related to ambiguity and practicality of some criteria lead to variability in interpretation and inter-observer inconsistency in reporting results from the same sets of data. Thus, we convened an international panel of 36 MDS experts and used an established modified Delphi process to develop consensus recommendations for updated response criteria that would be more reflective of patient-centered and clinically relevant outcomes in higher-risk MDS. Among others, the IWG 2023 criteria include changes in the hemoglobin threshold for complete remission (CR), the introduction of CR with limited count recovery (CRL) and CR with partial hematologic recovery (CRh) as provisional response criteria, elimination of marrow CR, and specific recommendations for standardization of time-to-event endpoints and the derivation and reporting of responses. The updated criteria should lead to better correlation between patient-centered outcomes and clinical trial results in an era of multiple emerging new agents with novel mechanisms of action. | |
| 700 | 1 | a Platzbecker, U4 aut |
| 700 | 1 | a Bewersdorf, JP4 aut |
| 700 | 1 | a Stahl, M4 aut |
| 700 | 1 | a Ades, L4 aut |
| 700 | 1 | a Borate, U4 aut |
| 700 | 1 | a Bowen, D4 aut |
| 700 | 1 | a Buckstein, R4 aut |
| 700 | 1 | a Brunner, A4 aut |
| 700 | 1 | a Carraway, HE4 aut |
| 700 | 1 | a Daver, N4 aut |
| 700 | 1 | a Diez-Campelo, M4 aut |
| 700 | 1 | a de Witte, T4 aut |
| 700 | 1 | a DeZern, AE4 aut |
| 700 | 1 | a Efficace, F4 aut |
| 700 | 1 | a Garcia-Manero, G4 aut |
| 700 | 1 | a Garcia, JS4 aut |
| 700 | 1 | a Germing, U4 aut |
| 700 | 1 | a Giagounidis, A4 aut |
| 700 | 1 | a Griffiths, EA4 aut |
| 700 | 1 | a Hasserjian, RP4 aut |
| 700 | 1 | a Hellstrom-Lindberg, Eu Karolinska Institutet4 aut |
| 700 | 1 | a Iastrebner, M4 aut |
| 700 | 1 | a Komrokji, R4 aut |
| 700 | 1 | a Kulasekararaj, AG4 aut |
| 700 | 1 | a Malcovati, L4 aut |
| 700 | 1 | a Miyazaki, Y4 aut |
| 700 | 1 | a Odenike, O4 aut |
| 700 | 1 | a Santini, V4 aut |
| 700 | 1 | a Sanz, G4 aut |
| 700 | 1 | a Scheinberg, P4 aut |
| 700 | 1 | a Stauder, R4 aut |
| 700 | 1 | a van de Loosdrecht, AA4 aut |
| 700 | 1 | a Wei, AH4 aut |
| 700 | 1 | a Sekeres, MA4 aut |
| 700 | 1 | a Fenaux, P4 aut |
| 710 | 2 | a Karolinska Institutet4 org |
| 773 | 0 | t Bloodd : American Society of Hematologyg 141:17, s. 2047-2061q 141:17<2047-2061x 1528-0020x 0006-4971 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:152940464 |
| 856 | 4 8 | u https://doi.org/10.1182/blood.2022018604 |
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Zeidan, AM
- Platzbecker, U
- Bewersdorf, JP
- Stahl, M
- Ades, L
- Borate, U
- visa fler...
- Bowen, D
- Buckstein, R
- Brunner, A
- Carraway, HE
- Daver, N
- Diez-Campelo, M
- de Witte, T
- DeZern, AE
- Efficace, F
- Garcia-Manero, G
- Garcia, JS
- Germing, U
- Giagounidis, A
- Griffiths, EA
- Hasserjian, RP
- Hellstrom-Lindbe ...
- Iastrebner, M
- Komrokji, R
- Kulasekararaj, A ...
- Malcovati, L
- Miyazaki, Y
- Odenike, O
- Santini, V
- Sanz, G
- Scheinberg, P
- Stauder, R
- van de Loosdrech ...
- Wei, AH
- Sekeres, MA
- Fenaux, P
- visa färre...
- Artiklar i publikationen
- Blood
- Av lärosätet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
